Skip to content

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Stage IVA Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8

This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk prostate cancer. SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period of time. This trial is evaluating if shorter duration radiation prevents cancer from coming back as well as the usual radiation treatment.

null

Participation Requirements

  • Sex:

    MALE
  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Pathologically (histologically or cytologically) proven diagnosis of adenocarcinoma of prostate cancer
* High-risk disease defined as having at least one or more of the following:

* cT3a-T3b by digital exam or imaging (American Joint Committee on Cancer \[AJCC\] 8th edition \[Ed.\]) Note: cT4 by imaging or on digital rectal exam is not allowed
* The patient's prostate specific antigen (PSA) \> 20 ng/mL prior to starting ADT Note: Patients taking a 5-alpha reductase inhibitor (ex finasteride or dutasteride) are eligible. The baseline PSA value should be doubled for PSAs taken while on 5-alpha reductase inhibitors
* Gleason Score of 8-10
* Pelvic node positive by conventional imaging with a short axis of at least 1.0 cm
* Prostate gland volume less than 100 cc prior to initiation of ADT as reported at time of biopsy or by separate measure with ultrasound or other imaging modalities including MRI or computed tomography (CT) scan
* No definitive clinical or radiologic evidence of metastatic disease outside of the pelvic nodes (M1a, M1b or M1c) on conventional imaging (i.e. bone scan, CT scan, MRI); Negative prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is an acceptable substitute
* Age \>= 18
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2
* No prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
* No prior radical prostatectomy
* Prior pharmacologic androgen ablation for prostate cancer is allowed only if the onset of androgen ablation (both luteinizing hormone releasing hormone \[LHRH\] agonist and oral anti-androgen) is =\< 185 days prior to registration
* Patients enrolled in NRG-GU009 must be enrolled in NRG-GU013 prior to radiation therapy treatment planning and start of radiation therapy

Study Location

CHUM - Centre Hospitalier de l'Universite de Montreal
CHUM - Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec
Canada

Contact Study Team

Primary Contact

Site Public Contact

[email protected]
514-890-8000
University Health Network-Princess Margaret Hospital
University Health Network-Princess Margaret Hospital
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Site Public Contact

[email protected]
416-946-4501
CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)
CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ)
Quebec City, Quebec
Canada

Contact Study Team

Primary Contact

Site Public Contact

[email protected]
Ottawa Hospital and Cancer Center-General Campus
Ottawa Hospital and Cancer Center-General Campus
Ottawa, Ontario
Canada

Contact Study Team

Primary Contact

Site Public Contact

613-761-4395
Study Sponsored By
NRG Oncology
Participants Required
More Information
Study ID: NCT05946213